Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: strong financial health and expansion plans are positive, but there's uncertainty in guidance and competitive positioning. The Q&A reveals management's optimism about product differentiation and market potential, yet lacks clarity on some strategic interactions. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Key Financial Performance
Cash Position Ended the first quarter of 2026 with approximately $172 million in cash, cash equivalents, and marketable securities. This balance does not include the $162 million in net proceeds from the underwritten common stock offering completed in April 2026. The offering extended the cash runway into 2030. Reasons for change include the successful completion of the stock offering and strong support from shareholders.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
IPF-related chronic cough program: Finalized study protocols for Phase III trials and identified global sites. First study to initiate this quarter, second study in the second half of the year.
Non-IPF-ILD-related chronic cough program: Proposed adaptive Phase II/III study to confirm dose and powering assumptions. Trial initiation expected in the second half of the year.
Refractory chronic cough program: Phase IIb parallel arm dose-ranging trial with 3 doses and placebo to initiate this quarter. Includes sample size reestimation (SSRE) with readout in Q4 2026.
Intellectual property expansion: Core method of treatment patent for IPF-related chronic cough issued in Europe, extending protection through 2039. Additional U.S. applications filed to potentially extend coverage through 2046.
Financial position: Ended Q1 2026 with $172 million in cash, excluding $162 million from April 2026 stock offering. Cash runway extended into 2030, covering critical clinical endpoints and pre-commercial activities.
Focus on chronic cough leadership: Aiming to become the leader in chronic cough treatment, addressing unmet patient needs and creating shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Risks: The company is awaiting FDA alignment and approval for multiple clinical trials, including the IPF-related chronic cough program and the non-IPF-ILD-related chronic cough program. Delays or rejections could impact timelines and strategic objectives.
Clinical Trial Execution Risks: The company is initiating multiple Phase II and Phase III trials, which involve complexities such as site identification, patient recruitment, and protocol adherence. Any delays or issues in execution could affect the company's progress.
Financial Risks: Although the company has extended its cash runway into 2030, the financial plan does not account for expenses related to the commercial launch of Haduvio or other clinical trials, which could pose future financial challenges.
Intellectual Property Risks: While the company has secured patents for its drug, the issuance of additional patents to extend coverage through 2046 is still pending. Any setbacks in securing these patents could impact competitive positioning.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Initiation of Phase III trials for IPF-related chronic cough: The company plans to initiate the first of two Phase III trials for IPF-related chronic cough in the current quarter, with the second trial expected to begin in the second half of 2026.
Non-IPF-ILD-related chronic cough program: The company intends to propose an adaptive Phase II/III study to the FDA, aiming to confirm dose and powering assumptions in Phase II before transitioning to a pivotal Phase III study. This trial is expected to start in the second half of 2026.
Phase IIb trial for refractory chronic cough: A Phase IIb parallel arm dose-ranging trial with three doses and placebo is planned to begin this quarter. The trial includes a sample size reestimation (SSRE) with a readout expected in Q4 2026.
Intellectual property advancements: The company is focused on extending patent coverage for its drug, with a core method of treatment patent for IPF-related chronic cough issued in Europe and additional applications filed in the U.S. that could extend coverage through 2046.
Financial runway and funding: The company has extended its cash runway into 2030, which includes funding for the development program for IPF-related chronic cough potentially through FDA approval, as well as planned Phase IIb and Phase III trials for non-IPF-ILD-related chronic cough and RCC.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the goal for the upcoming FDA meeting regarding the Phase IIb in non-IPF-ILD chronic cough?
A:The meeting is designed to discuss the intention for the ILD program, including submitting the full Phase IIb/III protocol for discussion. The focus will be on using the adaptive Phase II/III design to support approval, patient population details, dose selection, confirmation, and interim analysis to confirm power assumptions for the Phase III component.
Q:How does the company plan to balance resources and prioritize multiple programs?
A:The company leverages internal expertise, experienced CROs, and a tight team. They have added 10 new hires, including a pulmonologist and clinical staff, to scale appropriately for the trials.
Q:What is the competitive landscape for RCC and the impact of the P2X3 readout?
A:The company sees a large unmet need in the RCC space and believes the category can support multiple modalities. They emphasize their differentiation with a central and peripheral mechanism of action. Regardless of the P2X3 readout, they believe their data and investigator support will drive enrollment and interest in their study.
Q:How could inhaled formulation drugs in the IPF and PPF space impact Haduvio's opportunity?
A:The company believes Haduvio treats a more systemic chronic cough and can complement inhaled therapies. They see these therapies as helpful in defining the market and creating options, but Haduvio can coexist alongside them.
Q:Are there any data updates planned before the second half of 2027?
A:Yes, the SSRE (sample size reestimation) for the RCC trial is expected by Q4 of this year, providing an insightful readout on the trial.
Q:What are the key checkpoints for the SSRE in the RCC trial?
A:The SSRE will assess conditional power at the halfway point, aiming for 80%. If below 80%, the trial will upsize proportionately. Futility will also be assessed, with thresholds in the 30%-40% range.
Q:How does the company plan to expand its IP portfolio for Haduvio?
A:The company plans to build around the label with patents on titration schedules, dose adjustments, and other development findings. They aim to have multiple patents around the original base patent by the drug's launch.
Q:How impactful is dyspnea as a quality of life metric for IPF chronic cough patients?
A:Dyspnea is one of the top three complaints for IPF and ILD patients, alongside cough and fatigue. Addressing dyspnea can complement product uptake and adoption, as well as payer conversations.
Q:How does the company plan to minimize placebo response in the RCC clinical program?
A:The company is incorporating a placebo run-in period and ensuring well-controlled trial conduct to mitigate placebo response. They are also leveraging lessons from CNS trials to manage expectations and trial conduct.
Q:What are the most exciting developments to look forward to at ATS?
A:Key highlights include new sub-analyses from the CORAL study, presentations on cost-outs, and breathlessness data presented by experts in the field.
Q:Will the company track FVC in the Phase III IPF program?
A:Yes, FVC will be tracked throughout the 52-week period, but the smaller sample size compared to typical IPF trials may limit the ability to draw conclusions.
Q:What is the company's perspective on the upcoming P2X3 readout and its impact on their trials?
A:The company does not expect the P2X3 readout to impact their program significantly. They believe their drug works broadly across different cough counts and expect better performance compared to P2X3 therapies.
Q:What insights will be shared at the KOL event regarding non-IPF-ILD-related chronic cough trials?
A:Dr. Toby Maher, an ILD expert, will discuss the similarities and differences between IPF and ILD patients concerning cough, providing independent insights.
Q:How is the company addressing the enrollment of a truly addressable patient population in the RCC trial?
A:The company allows patients with various experiences, including those previously treated with P2X3 antagonists, as long as they meet eligibility requirements and have been off P2X3 for an appropriate period.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on how inhaled therapies might interact with Haduvio in the long term, stating that it would need to be learned over time. Additionally, they did not provide clear insights into how the evolving treatment landscape might specifically challenge RCC's potential.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATS
Analyst Day
Dr
III study
IPF ILD
IPF cough
Investor Analyst
Officer Chief
Phase II
Phase III
SSRE
Thursday
alignment FDA
assumption
comment
cough program
dose
event
lunch
lung
meeting
patent coverage
patient IPF
presentation
protocol
question
sample size
site
update
TRVI Transcript
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call summary presents a mixed picture: strong financial health and expansion plans are positive, but there's uncertainty in guidance and competitive positioning. The Q&A reveals management's optimism about product differentiation and market potential, yet lacks clarity on some strategic interactions. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Positive3-18
The earnings call summary indicates positive momentum with revenue growth, improved margins, and a reduced net loss. The company is investing in R&D and expanding manufacturing, suggesting confidence in future growth. The strategic initiatives and market recovery expectations further support a positive outlook. Despite a decrease in cash reserves, the financial health remains stable, and no significant risks were highlighted. These factors, along with strong revenue growth and improved financial metrics, suggest a positive stock price movement in the short term.
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed sentiment. Financial performance is stable with a cash runway into 2028, but increased expenses and lack of clear guidance on critical studies raise concerns. The Q&A session highlights positive interest from the medical community and strategic planning, yet management's vague responses on potential risks and uncertainties, like orphan drug designation, dampen optimism. Given these factors, the stock price is likely to remain neutral in the short term, with no significant catalysts for a strong movement.
Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-9
TRVI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
